Company / Capital Expenditures
Eton Pharmaceuticals, Inc. Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
-
FY2025
5-year range
$0 / $1.1M
FY2021-FY2025
Trend
-100.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $9,000 to $0 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, capital expenditures decreased 100.0% year-over-year.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.63 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0 | -100.0% |
| FY2024 | $38.0K | +322.2% |
| FY2023 | $9.0K | -82.0% |
| FY2022 | $50.0K | -95.4% |
| FY2021 | $1.1M | +364.4% |
| FY2020 | $236.0K | +81.5% |
| FY2019 | $130.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026